$83.45−1.39 (−1.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Iradimed (IRMD) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~19.0%/yr (FY21→FY25), net margin 26.8%; free cash flow runs at 74% of net income. Check the accrual gap.
The four lines that matter · FY21–FY25
Revenue ($M)▲14.4%
83.8
FY21→FY25CAGR +19.0%/yr
Net income ($M)▲16.9%
22.5
one-off year: see footnoteCAGR +24.6%/yr
Free cash flow ($M)▼1.7%
16.5
FY21→FY25CAGR +12.0%/yr
Diluted EPS▲16.7%
1.75
FY21→FY25CAGR +24.0%/yr
What the receipts whisper · what a headline number hides
Share count
+2.1%
12.6mn → 12.9mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$8.4M
steady at 10.0% of revenue (−4.5% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
27¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 76.6% → 76.7%. Net margin 26.8% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 89,340.0 | 83,814.0 | 73,242.0 | 65,562.3 | 53,303.1 | 41,814.6 | ▲14.4% | +19.0% |
Cost of revenue | 21,878.0 | 19,490.0 | 16,892.0 | 15,404.0 | 12,020.7 | 9,764.7 | ▲15.4% | +18.9% |
Gross profit | 67,462.0 | 64,324.0 | 56,350.0 | 50,158.3 | 41,282.4 | 32,049.9 | ▲14.2% | +19.0% |
Research & development | 3,288.0 | 2,975.0 | 2,832.0 | 2,858.7 | 2,278.1 | 1,905.0 | ▲5.0% | +11.8% |
Selling, general & admin | 17,503.0 | 17,782.0 | 15,937.0 | 15,122.1 | 10,697.1 | 9,771.5 | ▲11.6% | +16.1% |
Total operating expenses | 38,601.0 | 38,177.0 | 34,385.0 | 30,122.8 | 25,654.8 | 22,232.2 | ▲11.0% | +14.5% |
Operating incomefeeds ROC rank | 28,861.0 | 26,147.0 | 21,965.0 | 20,035.5 | 15,627.6 | 9,817.7 | ▲19.0% | +27.7% |
Other income, net | 2,256.0 | 2,214.0 | 2,310.0 | 1,702.8 | 553.1 | 18.6 | — | — |
Pretax income | 31,117.0 | 28,361.0 | 24,275.0 | 21,738.3 | 16,180.7 | 9,836.3 | ▲16.8% | +30.3% |
Income tax | 7,132.0 | 5,881.0 | 5,041.0 | 4,545.5 | 3,352.3 | 510.8 | ▲16.7% | +84.2% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 23,985.0 | 22,480.0 | 19,234.0 | 17,192.8 | 12,828.5 | 9,325.5 | ▲16.9% | +24.6% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 1.87 | 1.75 | 1.50 | 1.35 | 1.02 | 0.74 | ▲16.7% | +24.0% |
Diluted shares (mn) | 12.88 | 12.85 | 12.78 | 12.72 | 12.64 | 12.59 | ▲0.5% | +0.5% |
| Margins | ||||||||
Gross margin68th pct in Healthcare | 75.5% | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% | ▼0.2pp | +0.1pp |
Operating margin | 32.3% | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | ▲1.2pp | +7.7pp |
Net margin91st pct in Healthcare | 26.8% | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | ▲0.6pp | +4.5pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 5% vs a 21% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-06 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Iradimed's revenue last fiscal year?
Iradimed reported revenue of $83.8M in fiscal 2025, up 14.4% from fiscal 2024.
What was Iradimed's net income?
Iradimed reported net income of $22.5M in fiscal 2025, a net margin of 26.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

